Hunan Zhaotai Yongren Biotech Co. Ltd.   Report issue

For profit Phase 1
Founded: Beijing China (1992)
Status: Defunct (2021)

Organization Overview

First Clinical Trial
2016
NCT03060343
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2016

Timeline

NOW
  • Now

Active Ingredients

Drugs in Phase 1 Trials (1)

cytotoxic t cells (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Carcinoma, Non-Small-Cell Lung (Phase 1)

Lung Neoplasms (Phase 1)

Overview

  • Highest Phase: Phase 1
  • # of Trials: 1
  • # of Trial APIs: 1